Sign in
CompletedPhase 2

Efficacy of early intravenous high-dose vitamin C in post-cardiac arrest shock: a multicenter, randomized controled to standard treatment, open label trial.

Key facts

Who runs it
Centre Hospitalier Bethune Beuvry
Where
France14 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
234 people enrolled
Started
27 Dec 2023
Ended
14 Jul 2026
Type of study
Interventional
Record updated
23 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • patients still comatose (Glasgow coma scale < 8)
  • an OHCA of presumed cardiac origin with ROSC < 60 min
  • treated with a norepinephrin or an epinephrin continuous infusion ≥ 0.2µg/kg/h, within 4 hours after OHCA, during at least 30 min/h to maintain mean arterial pressure (MAP) ≥ 65 mmHg

Who cannot take part

  • patients already treated with vit-C
  • pre-existent severe chronic kidney disease (glomerular filtration rate < 30ml/min)
  • moribound or chronic disease (life expectancy <1 an)
  • OHCA from evident extracardiac cause (trauma, bleeding, poisoning, etc..)
  • Hypersensitivity of active substance or méthyl parahydroxybenzoate or dipropyl
  • inclusion in another interventional study in cardiac arrest or post CA
  • Contraindication to vitamine C (glucose-6-phosphate deshydrogenase deficiency; hemochromatosis)
  • minor
  • Patient with legal protective measures
  • Patient not covered by French national health insurance
  • known vit-C deficit
  • Patient with derpived freedom
  • Hyperoxaluria
  • Hystory of urolithiasis
  • pregnant women
  • interval between OHCA and randomization > 4 hours
  • extracorporeal circulatory assistance requirement in the first 4 hours after OHCA

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Our main objective is to assess the efficacy of IV high-dose vit-C to reduce the need for vasopressor within the first 3 days in patients who suffered from an OHCA with a post-CA shock.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
23 September 2026